Whilst polyneuropathy, the hallmark phenotypic feature for which TTR gene silencers are licensed in ATTRv (4, 5), is unequivocally caused by amyloid deposits it remains uncertain to what extent amyloid deposits contribute to other common organ manifestations in patients with ATTR amyloidosis such as gastrointestinal disturbance, lumbar canal stenosis and joint pains despite their almost universal presence in the relevant tissue. Here, TTR is linked to amyloidosis.